Cornercap Investment Counsel’s Vanda Pharmaceuticals VNDA Stock Holding History

Cornercap Investment Counsel’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-16,101	Closed	-$75.5K	–	541
2024 Q3	$75.5K	Sell	16,101 -16,460	-51%	-$88.2K	0.02%	495
2024 Q2	$184K	Sell	32,561 -334	-1%	-$1.73K	0.03%	546
2024 Q1	$135K	Hold	32,895	–	–	0.02%	581
2023 Q4	$139K	Hold	32,895	–	–	0.02%	552
2023 Q3	$142K	Sell	32,895 -108	-0.3%	-$600	0.03%	521
2023 Q2	$217K	Buy	+33,003	New	+$212K	0.04%	499
2022 Q2	–	Sell	-76,041	Closed	-$860K	–	692
2022 Q1	$860K	Buy	76,041 +10,077	+15%	+$132K	0.1%	370
2021 Q4	$1.03M	Buy	+65,964	New	+$1.15M	0.15%	287

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Cornercap Investment Counsel's VNDA Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 16,101 shares — an estimated $75.5K sold.

Cornercap Investment Counsel first reported a position in VNDA in Q4 2021 and held it in 8 quarters. The position peaked at $1.03M in Q4 2021. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

Cornercap Investment Counsel reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Cornercap Investment Counsel sold 16,101 Vanda Pharmaceuticals shares in Q4 2024, an estimated $75.5K.
Cornercap Investment Counsel first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 8 quarters.
Cornercap Investment Counsel's Vanda Pharmaceuticals position peaked at $1.03M in Q4 2021.
146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.